Company: BIAF
Filing Date: 2025-11-07
Form Type: DEF 14A
Source: 0001493152-25-021269
Chunk: 10

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-07
Form: DEF 14A
Chunk 10
---
 how to revoke or submit new voting instructions.

Who will pay for the cost of this proxy solicitation?

The Company will pay for the cost of soliciting proxies. Some of the Company’s directors, officers, or employees may (for no additional compensation) solicit proxies in person or by telephone, email, or facsimile transmission. Brokers and other nominees will be requested to solicit proxies or authorizations from beneficial owners and will be reimbursed for their reasonable expenses.

| 5 |

<div align='center'>PROPOSAL NO. 1

APPROVAL OF THE WARRANT EXERCISE</div>

We are seeking stockholder approval for the issuance of up to 271,500 shares of our Common Stock upon the exercise of the August 2025 Warrants, which includes (i) 223,831 shares of our Common Stock issuable upon exercise of August 2025 Common Warrants issued in our Private Placement (as defined below) and (ii) 47,669 shares of our Common Stock issuable upon exercise of Inducement Warrants, each of which closed on August 14, 2025, as contemplated by Nasdaq Listing Rules.

On August 13, 2025, we entered into a securities purchase agreement (the “ Purchase Agreement”) with certain institutional and accredited investors, pursuant to which we agreed to issue and sell, in a private placement (the “ Private Placement”), (i) 990 shares of the Company’s newly designated Series B Convertible Preferred Stock, with a par value $0.001 per share and stated value of $1,000 per share initially convertible into 143,476 shares (the “Conversion Shares”) of our Common Stock at an initial conversion price of $6.90 per share and (ii) warrants (the “Warrants”) to purchase up to 223,831 shares of the Company’s Common Stock at an exercise price of $10.56 per share of Common Stock.

On August 13, 2025, we entered into a warrant inducement agreement (the “ Inducement Agreement”) with certain holders (the “ Holders”) of outstanding warrants to purchase 15,000 shares of Common Stock issued in a private placement offering that closed on August 5, 2024 with a current exercise price of $37.50 per share (the “ August 2024 Warrants”), and 21,666 shares of Common Stock originally issued on October 21, 2024 with a current exercise price of $45.00 per